# Biotech Daily Digest — 2026-01-29

**32 items from 3 sources**

## Summary by Source

- Endpoints News: 11 items
- Fierce Biotech: 9 items
- arXiv q-bio: 12 items


## Endpoints News

- **[Agomab anticipates $182M IPO as it builds fibrosis pipeline](https://endpoints.news/agomab-anticipates-182m-ipo-as-it-builds-fibrosis-pipeline/)**  
  _Thu, 29 Jan 2026 14:13:32 +0000_  
  Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO.

 The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol ...

- **[AstraZeneca makes $15B bet on China to expand manufacturing and R&D](https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/)**  
  _Thu, 29 Jan 2026 13:39:17 +0000_  
  AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that's become a go-to place for drug R&D and industry dealmaking in the past year.

 The UK pharma ...

- **[Roche predicts its breast cancer pill could become its biggest-selling drug](https://endpoints.news/roche-predicts-its-breast-cancer-pill-could-become-its-biggest-selling-drug/)**  
  _Thu, 29 Jan 2026 12:11:54 +0000_  
  With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty.

 Management is hugely confident ...

- **[Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff](https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/)**  
  _Thu, 29 Jan 2026 11:46:10 +0000_  
  Sanofi says it will be able to spend between €14 billion and €15 billion on M&A deals this year while still being able to meet its financial commitments.

 “It doesn’t mean that we will make ...

- **[Flagship's Repertoire gets another autoimmune partner in Lilly](https://endpoints.news/flagships-repertoire-gets-another-autoimmune-partner-in-lilly/)**  
  _Thu, 29 Jan 2026 11:30:20 +0000_  
  Repertoire Immune Medicines has added a fourth pharmaceutical partner by teaming up with Eli Lilly.

 The Indianapolis pharma joins Bristol Myers Squibb and Genentech in allying with Repertoire on so-called tolerizing vaccines for autoimmune diseases ...

- **[ChenMed CEO warns against GLP-1s for seniors](https://endpoints.news/chenmed-ceo-warns-against-glp-1s-for-seniors/)**  
  _Wed, 28 Jan 2026 23:12:32 +0000_  
  ChenMed CEO Chris Chen said the primary care chain isn’t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients.

 Speaking on a ...

- **[Round three of IRA negotiations is expected to be ‘manageable’ for pharma](https://endpoints.news/round-three-of-ira-negotiations-is-expected-to-be-manageable-for-pharma/)**  
  _Wed, 28 Jan 2026 21:19:03 +0000_  
  Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program.

 On Tuesday, CMS

- **[Oral Rogaine maker Veradermics looks to raise $181M from IPO](https://endpoints.news/oral-rogaine-maker-veradermics-looks-to-raise-181m-from-ipo/)**  
  _Wed, 28 Jan 2026 19:18:51 +0000_  
  Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO.

 The Connecticut biotech will garner that amount if it sells ...

- **[FDA asks court to pause Louisiana's abortion pill fight](https://endpoints.news/fda-asks-court-to-pause-louisianas-abortion-pill-fight/)**  
  _Wed, 28 Jan 2026 19:18:46 +0000_  
  The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drug’s safety protocols.

 An ongoing mifepristone review could result in ...

- **[Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs](https://endpoints.news/eikon-seeks-273m-ipo-with-pipeline-led-by-chinese-cancer-drugs/)**  
  _Wed, 28 Jan 2026 15:25:44 +0000_  
  A biotech led by former Merck top brass with a pipeline anchored by three cancer drugs linked to Chinese drug developers is pushing ahead with an IPO, even while off its peak valuation.

 Eikon Therapeutics ...

- **[Hengrui blazes trail as Chinese drugmakers aspire to go multinational](https://endpoints.news/hengrui-blazes-trail-as-chinese-drugmakers-aspire-to-go-multinational/)**  
  _Wed, 28 Jan 2026 15:00:06 +0000_  
  Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value.

 Once virtually unknown outside of China, the company has made its name overseas via an R&D engine that ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/roche-diagnostics-biz-nudges-2-fy-china-headwinds-buffet-asia-pacific-sales" hreflang="en">Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales</a>](https://www.fiercebiotech.com/medtech/roche-diagnostics-biz-nudges-2-fy-china-headwinds-buffet-asia-pacific-sales)**  
  _Jan 29, 2026 4:05am_  
  Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.

- **[<a href="https://www.fiercebiotech.com/biotech/repertoire-adds-eli-lilly-its-range-big-pharma-partners-85m-upfront-autoimmune-pact" hreflang="en">Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $1.9B</a>](https://www.fiercebiotech.com/biotech/repertoire-adds-eli-lilly-its-range-big-pharma-partners-85m-upfront-autoimmune-pact)**  
  _Jan 28, 2026 4:08pm_  
  With three Big Pharma collaborations already under its belt, Flagship Pioneering spinout Repertoire Immune Medicines has picked up one more—and its biggest yet—in a further validation of the company’s immune system decoding platform.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-drops-100m-fibrosis-drug-phase-2-pipeline-part-clearout" hreflang="en">Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout</a>](https://www.fiercebiotech.com/biotech/roche-drops-100m-fibrosis-drug-phase-2-pipeline-part-clearout)**  
  _Jan 29, 2026 6:31am_  
  Roche has waved goodbye to an inflammation drug from Kiniksa—as well as the $100 million the pharma paid for the therapy.

- **[<a href="https://www.fiercebiotech.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities" hreflang="en">AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities</a>](https://www.fiercebiotech.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities)**  
  _Jan 29, 2026 5:51am_  
  AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

- **[<a href="https://www.fiercebiotech.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year" hreflang="en">The new rules of biopharma M&amp;A: 4 trends driving dealmaking this year</a>](https://www.fiercebiotech.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year)**  
  _Jan 28, 2026 1:36pm_  
  As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

- **[<a href="https://www.fiercebiotech.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m" hreflang="en">Halozyme catches M&amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M</a>](https://www.fiercebiotech.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m)**  
  _Jan 28, 2026 12:05pm_  
  Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.

- **[<a href="https://www.fiercebiotech.com/research/new-compound-diminishes-brain-tumors-mice-sparking-hope-glioblastoma-pill" hreflang="en">New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill</a>](https://www.fiercebiotech.com/research/new-compound-diminishes-brain-tumors-mice-sparking-hope-glioblastoma-pill)**  
  _Jan 27, 2026 11:46pm_  
  Scientists have discovered a molecule that shrinks brain tumors in mice, raising hopes that the compound could one day become a pill to treat glioblastoma, one of the world’s most pernicious cancers.

- **[<a href="https://www.fiercebiotech.com/research/charles-river-coo-says-animal-testing-evolution-and-not-revolution-company-digs-new" hreflang="en">Reducing animal testing 'an evolution and not a revolution' for life sci R&amp;D, Charles River's incoming CEO says</a>](https://www.fiercebiotech.com/research/charles-river-coo-says-animal-testing-evolution-and-not-revolution-company-digs-new)**  
  _Jan 28, 2026 10:15am_  
  The pursuit of animal-sparing research methods is “definitely an evolution and not a revolution,” Charles River’s executive vice president and chief operating officer, Birgit Girshick, said in a recent interview with Fierce. Under a leadership transition unveiled earlier this month, Girshick is set to ascend to the CE…

- **[<a href="https://www.fiercebiotech.com/medtech/td-cowen-picks-top-3-medtech-prospects-across-its-bones-bots-and-no-more-shots-portfolio" hreflang="en">TD Cowen picks top 3 medtech prospects across its 'Bones, Bots, and No More Shots' portfolio</a>](https://www.fiercebiotech.com/medtech/td-cowen-picks-top-3-medtech-prospects-across-its-bones-bots-and-no-more-shots-portfolio)**  
  _Jan 27, 2026 10:37am_  
  TD Cowen analysts Mathew Blackman and Drew Ranieri have named their top three medtech picks under their evolving “Bones, Bots and No More Shots” portfolio coverage.


## arXiv q-bio

- **[CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination](https://arxiv.org/abs/2601.20343)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20343v1 Announce Type: new 
Abstract: Each T cell typically carries a specific T-cell receptor (TCR) that determines its specificity against an epitope presented by the HLA complex on a target cell. Antigenic challenge triggers the expansion of reactive cells within a diverse pool of T cells with randomly g…

- **[Promotion of cooperation in deme-structured populations with growth-merging dynamics](https://arxiv.org/abs/2601.20416)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20416v1 Announce Type: new 
Abstract: The spatial structure of populations may promote the emergence and maintenance of cooperation. Cooperation in the prisoner's dilemma is favored under specific update rules in evolutionary graph theory models with one individual per node of a graph, but this effect vanis…

- **[Assembling the Mind's Mosaic: Towards EEG Semantic Intent Decoding](https://arxiv.org/abs/2601.20447)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20447v1 Announce Type: new 
Abstract: Enabling natural communication through brain-computer interfaces (BCIs) remains one of the most profound challenges in neuroscience and neurotechnology. While existing frameworks offer partial solutions, they are constrained by oversimplified semantic representations an…

- **[Noise-induced excitability: bloom, bust and extirpation in autotoxic population dynamics](https://arxiv.org/abs/2601.20670)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20670v1 Announce Type: new 
Abstract: Species populations often modify their environment as they grow. When environmental feedback operates more slowly than population growth, the system can undergo boom-bust dynamics, where the population overshoots its carrying capacity and subsequently collapses. In extr…

- **[Cross-Country Learning for National Infectious Disease Forecasting Using European Data](https://arxiv.org/abs/2601.20771)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20771v1 Announce Type: new 
Abstract: Accurate forecasting of infectious disease incidence is critical for public health planning and timely intervention. While most data-driven forecasting approaches rely primarily on historical data from a single country, such data are often limited in length and variabil…

- **[Optimal illness policy for an unethical daycare center](https://arxiv.org/abs/2601.20123)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20123v1 Announce Type: cross 
Abstract: While businesses are typically more profitable if their workers and communities are minimally exposed to diseases, the same is not true for daycare centers. Here it is shown that a daycare center could maximize its profits by maintaining a population of sick children…

- **[Control systems for synthetic biology and a case-study in cell fate reprogramming](https://arxiv.org/abs/2601.20135)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20135v1 Announce Type: cross 
Abstract: This paper gives an overview of the use of control systems engineering in synthetic biology, motivated by applications such as cell therapy and cell fate reprogramming for regenerative medicine. A ubiquitous problem in these and other applications is the ability to co…

- **[Implications of temporal sampling in voltage imaging microscopy](https://arxiv.org/abs/2601.20236)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20236v1 Announce Type: cross 
Abstract: Significance: Voltage imaging microscopy has emerged as a powerful tool to investigate neural activity both in vivo and in vitro. Various imaging approaches have been developed, including point-scanning, line-scanning and wide-field microscopes, however the effects of…

- **[An explainable framework for the relationship between dementia and glucose metabolism patterns](https://arxiv.org/abs/2601.20480)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20480v1 Announce Type: cross 
Abstract: High-dimensional neuroimaging data presents challenges for assessing neurodegenerative diseases due to complex non-linear relationships. Variational Autoencoders (VAEs) can encode scans into lower-dimensional latent spaces capturing disease-relevant features. We propo…

- **[WFR-MFM: One-Step Inference for Dynamic Unbalanced Optimal Transport](https://arxiv.org/abs/2601.20606)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20606v1 Announce Type: cross 
Abstract: Reconstructing dynamical evolution from limited observations is a fundamental challenge in single-cell biology, where dynamic unbalanced optimal transport provides a principled framework for modeling coupled transport and mass variation. However, existing approaches r…

- **[AGFS-Tractometry: A Novel Atlas-Guided Fine-Scale Tractometry Approach for Enhanced Along-Tract Group Statistical Comparison Using Diffusion MRI Tractography](https://arxiv.org/abs/2507.10601)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2507.10601v2 Announce Type: replace 
Abstract: Diffusion MRI (dMRI) tractography is currently the only method for in vivo mapping of the brain's white matter (WM) connections. Tractometry is an advanced tractography analysis technique for along-tract profiling to investigate the morphology and microstructural pr…

- **[Quantification of dual-state 5-ALA-induced PpIX fluorescence: Methodology and validation in tissue-mimicking phantoms](https://arxiv.org/abs/2510.18387)**  
  _Thu, 29 Jan 2026 00:00:00 -0500_  
  arXiv:2510.18387v2 Announce Type: replace-cross 
Abstract: Quantification of protoporphyrin IX (PpIX) fluorescence in human brain tumours has the potential to significantly improve patient outcomes in neuro-oncology, but represents a formidable imaging challenge. Protoporphyrin is a biological molecule which interacts…
